Dr. Bose is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1515 Holcombe Blvd
Houston, TX 77030Phone+1 713-792-6161Fax+1 713-794-4534
Education & Training
- University of Oklahoma Health Sciences CenterFellowship, Hematology and Medical Oncology, 2007 - 2010
- University of Oklahoma Health Sciences Center2007 - 2010
- Henry Ford Health/Henry Ford HospitalResidency, Internal Medicine, 2005 - 2007
- Spokane Teaching Health CenterInternship, Internal Medicine, 2004 - 2005
- Medical College and Hospital KolkataClass of 2002
Certifications & Licensure
- FL State Medical License 2021 - Present
- GA State Medical License 2022 - 2026
- TX State Medical License 2015 - 2026
- AL State Medical License 2023 - 2025
- AZ State Medical License 2022 - 2025
- LA State Medical License 2022 - 2025
- MS State Medical License 2022 - 2025
- American Board of Internal Medicine Hematology
- Join now to see all
Awards, Honors, & Recognition
- Physician’s Recognition Award with Commendation American Medical Association, 2011
- University Honors University of Calcutta, 1997
- First Certificate of Honors in Biochemistry University of Calcutta, 1995
- Join now to see all
Clinical Trials
- Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
- Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia Start of enrollment: 2017 Mar 20
- Isavuconazole in Preventing Invasive Fungal Infections in Adult Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome and Neutropenia Start of enrollment: 2017 Mar 28
Publications & Presentations
PubMed
- Ruxolitinib for myelofibrosis: The earlier, the better?Prithviraj Bose, Pankit Vachhani
Cancer. 2024-12-15 - Investigational drugs in early phase trials for myelofibrosis.Sankalp Arora, Pankit Vachhani, Prithviraj Bose
Expert Opinion on Investigational Drugs. 2024-11-27 - Long-term follow-up of a phase 2 study of all-trans retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin in acute promyelocytic leukemia.Wei-Ying Jen, Jennifer Marvin-Peek, Hagop M Kantarjian, Yesid Alvarado, Gautam Borthakur
Cancer. 2024-11-25
Journal Articles
- Mutational Landscape of myelodysplastic/myeloproliferative Neoplasm – Unclassifiable (MDS/MPN-U)Aziz Nazha, Rami S Komrokji, Andrew Sochacki, Mikkael A Sekeres, Prithviraj Bose, Courtney D DiNardo, Hagop M Kantarjian, Srdan Verstovsek, Sanam Loghavi, Jaroslaw P M..., Blood
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Ri...Joshua F Zeidner, Mark R Litzow, Jeffrey E Lancet, Prithviraj Bose, Raoul Tibes, Ivana Gojo, Richard F Little, Judith E Karp, Leukemia Research
- Cyclin dependent kinase inhibitor therapy for hematologic malignanciesBose P, Simmons GL, Grant S, Expert Opin Investig Drugs, 5/6/2013
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Constitutively Activated STAT3 Induces the Production of PTX3 That Contributes to the Induction of Bone Marrow Reticulin Fibrosis in Patient with CLLPrithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase II Trial of Azacitidine (AZA) in Combination with Ruxolitinib (RUX) in Myelodysplastic Syndrome/Myeloproliferative Neoplasms (MDS/MPNs)Prithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Phase 2 Study of Ruxolitinib (RUX) in Combination with 5-Azacitidine (AZA) in Patients (pts) with MyelofibrosisPrithviraj Bose, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Join now to see all
Lectures
- Present Strategies and Future Directions: Treating MDS and MPN61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Combined Ibrutinib and Venetoclax in Patients with Treatment-Naïve High-Risk Chronic Lymphocytic Leukemia (CLL)2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Novel BET Protein Degrader-Based Combinations Exert Lethality Against Human AML Resistant to BET Inhibitors Due to Increased Activity of β-Catenin-TCF7L2- MYC Axis2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Authored Content
- Final Results of a Randomized Multicenter Phase II Study of Alvocidib, Cytarabine, and Mitoxantrone Versus Cytarabine and Daunorubicin (7+3) in Newly Diagnosed High-Risk Acute Myeloid Leukemia (AML)August 2018
- Ibrutinib, Fludarabine, Cyclophosphamide, and Obinutuzumab (GA101) (iFCG) Treatment for First-Line Therapy of Patients with CLL with Mutated IGHV and Without Deletion 17pOctober 2017
Press Mentions
- Asymptomatic or Minimally Symptomatic MyelofibrosisNovember 4th, 2024
- Innovative Developments in Myelofibrosis Treatment OptionsAugust 16th, 2024
- Momelotinib Maintains Superiority over Danazol for Myelofibrosis with AnemiaDecember 14th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: